No Data
No Data
Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.
① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?
AI empowers the FDA! Drug approvals hit the 'fast-forward' button, and a large number of pharmaceutical companies may welcome a 'Gold' period.
The USA Food and Drug Administration (FDA) announced an accelerated plan on Thursday to fully implement AI applications across all subsidiary institutions by June 30, aiming to significantly expedite the approval process for new pharmaceuticals.
JW THERAP-B: 2024 ANNUAL REPORT
Express News | Hong Kong pharmaceutical stocks continue to rise, IMMUNEONCO-B increases by over 11%.
JW THERAP-B (02126) grants Juno a non-exclusive license for the JW sLVV production process and related technical knowledge.
JW THERAP-B (02126) announced that the company has reached an agreement with one of its major shareholders and related parties, Juno, regarding ...
JW THERAP-B (02126) is issuing 0.4881 million shares according to the stock plan.
JW THERAP-B (02126) issued an announcement that on March 21, 2025, the company will issue based on the share plan...